We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-30.53%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$164M
AUM Growth
-$118M
Cap. Flow
-$30.4M
Cap. Flow %
-18.55%
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$16.4M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$21.8M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$13.4M
3
ARGX icon
argenx
ARGX
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Miscellaneous 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
1
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$45.1M 27.58%
389,842
– –
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$36.2M 22.09%
2,331,534
– –
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$26.1M 15.94%
3,370,982
– –
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$15.7M 9.58%
1,423,794
– –
TPTX
5
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$13.8M 8.42%
+308,686
New +$16.4M
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$8.8M 5.38%
337,291
– –
CTMX icon
7
CytomX Therapeutics
CTMX
$699M
$6.56M 4.01%
855,437
– –
VIRX
8
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.17M 0.71%
80,283
– –
AUTL
9
Autolus Therapeutics
AUTL
$623M
$238K 0.15%
39,740
– –
ARGX icon
10
argenx
ARGX
$64B
– –
-71,700
Closed -$11.5M
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-215,570
Closed -$13.4M
ARQL
12
DELISTED
Arqule Inc
ARQL
– –
-1,094,210
Closed -$21.8M

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2020 Portfolio in Review

As of Q1 2020, MPM BioImpact held 13 positions worth $164M, down 42% from $282M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

MPM BioImpact withdrew a net $30.4M in Q1 2020, closing 3 positions. Its most notable exit was Arqule Inc, an estimated $21.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous.

Against the trend, MPM BioImpact opened a new position in Turning Point Therapeutics, Inc. Common Stock worth $13.8M.

  • MPM BioImpact's largest Q1 2020 buy was Turning Point Therapeutics, Inc. Common Stock: 308,686 shares worth $13.8M.
  • MPM BioImpact fully exited Arqule Inc in Q1 2020, selling an estimated $21.8M.
  • MPM BioImpact's ten largest holdings make up 100% of its $164M portfolio in Q1 2020.
  • MPM BioImpact opened 1 new position and closed 3 in Q1 2020.
  • MPM BioImpact's portfolio value fell 42% quarter-over-quarter to $164M.

Based on MPM BioImpact's 13F filing for Q1 2020, filed 13 May 2020.